Skip to main content

PROMISSE: progress in understanding pregnancy complications in patients with SLE

Pregnancy complications in women with the antiphospholipid syndrome (APS) and/or SLE include recurrent miscarriage, preeclampsia, placental insufficiency, and intrauterine growth restriction (IUGR). The mechanisms leading to placental and fetal injury in vivo are incompletely understood and treatment remains sub-optimal. We have identified complement as an early effector in pregnancy loss and/or IUGR associated with placental inflammation in a mouse model of APS and shown that complement activation drives angiogenic imbalance, placental insufficiency and endothelial injury [13] (Figure 1). The PROMISSE Study (Predictors of Pregnancy Outcome: Biomarkers in Antiphospholipid Antibody Syndrome and Systemic Lupus Erythematosus) is a first-time effort to translate our novel findings in mice to humans and determine examine the role of complement as a mediator of complications in patients with antiphospholipid (aPL) antibodies and/or SLE. The following discoveries from PROMISSE will be summarized: lupus anticoagulant is the most powerful predictor of poor pregnancy outcomes in aPL-positive patients [4]; activation of complement early in pregnancy can be detected in the blood of women destined to have preeclampsia; circulating anti-angiogenic factors are biomarkers that predict preeclampsia in patients with SLE and/or aPL antibodies and can be released by products of complement activation; and mutations in complement pathway genes that lead to uncontrolled complement activation are associated with preeclampsia in pregnant patients with SLE and/or aPL antibodies [5]. These findings bring us to closer to identifying those at highest risk for pregnancy complications and intervening to block pathways of injury, such as complement.

figure1

Figure 1

References

  1. 1.

    Girardi G, Berman J, Redecha P, Spruce L, Thurman JM, Kraus D, Hollmann TJ, Casali P, Caroll MC, Wetsel RA, Lambris JD, Holers VM, Salmon JE: Complement C5a receptors and neutrophils mediate fetal injury in the antiphophospholipid syndrome. J Clin Invest. 2003, 112: 1644-1654.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  2. 2.

    Salmon JE, Girardi G, Lockshin MD: The antiphospholipid syndrome - a disorder initiated by inflammation: implications for therapy of pregnant patients. Nat Clin Pract Rheumatol. 2007, 3: 140-147. 10.1038/ncprheum0432.

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    Lynch AM, Salmon JE: Dysregulated complement activation as a common pathway of injury in preeclampsia and other pregnancy complications. Placenta. 2010, 31: 561-567. 10.1016/j.placenta.2010.03.010.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  4. 4.

    Lockshin MD, Kim M, Laskin CA, Guerra M, Branch DW, Merrill J, Petri M, Porter F, Sammaritano L, Stephenson MD, Buyon J, Salmon JE: Lupus anticoagulant, but not anticardiolipin antibody, predicts adverse pregnancy outcome in patients with antiphospholipid antibodies. Arthritis Rheum. 2012, 64: 2311-2318. 10.1002/art.34402.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  5. 5.

    Salmon JE, Heuser C, Triebwasser M, Liszewski KM, Kavanagh D, Roumenina L, Branch DW, Goodship T, Fremeaux-Bacchi V, Atkinson JP: Mutations in complement regulatory proteins predispose to preeclampsia. PLoS Med. 2011, 8: e1001013-10.1371/journal.pmed.1001013.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work is presented on behalf of the PROMISSE Investigators (J Buyon, M Kim, MD Lockshin, CA Laskin, DW Branch, J Merrill, M Petri, L Sammaritano, M Stephenson) and the PROMISSE Collaborators (JP Atkinson, M Triebwasser, SA Karumanchi). This research is supported by grant NIH/NIAMS RO1 AR49772.

Author information

Affiliations

Authors

Corresponding author

Correspondence to JE Salmon.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Cite this article

Salmon, J. PROMISSE: progress in understanding pregnancy complications in patients with SLE. Arthritis Res Ther 14, A39 (2012). https://doi.org/10.1186/ar3973

Download citation

Keywords

  • Systemic Lupus Erythematosus
  • Preeclampsia
  • Pregnancy Outcome
  • Complement Activation
  • Pregnancy Complication